Communiqués Seres Therapeutics, Inc.

Actions

MCRB

US81750R2013

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
4,870 ^USD	+1,04 %		+0,83 %	-67,27 %

05/08	Seres Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
08/07	Seres Therapeutics annonce des données cliniques préliminaires démontrant le potentiel de SER-155 dans l'entérocolite liée aux inhibiteurs de points de contrôle immunitaire	CI

Communiqués

05/08	Seres Therapeutics: Q2 Earnings Snapshot	AQ
05/08	Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs	AQ
08/07	Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment	AQ
25/06	Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis	AQ
08/06	Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027	AQ
05/06	Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027	AQ
12/05	Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference	AQ
05/05	Seres Therapeutics: Q1 Earnings Snapshot	AQ
05/05	Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
04/05	Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease	AQ
20/04	Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026	AQ
09/04	Seres Therapeutics to Present at CARB-X Investor Day	AQ
12/03	Seres Therapeutics: Q4 Earnings Snapshot	AQ
12/03	Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates	AQ
02/03	Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates	AQ
12/02	Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases	AQ
06/01	Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy	AQ
24/11	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference	AQ
05/11	Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates	AQ
30/10/25	Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025	AQ
29/10/25	Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155	AQ
14/10/25	Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant	AQ
23/09/25	Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway	AQ
27/08/25	Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference	AQ
06/08/25	Seres Therapeutics: Q2 Earnings Snapshot	AQ